Hormel Foods HRL
Consumer Defensive · Packaged Foods · Synthos Deep Dive · 2026-07-03
The Overview
Hormel makes the food in your pantry: SPAM, Skippy peanut butter, Planters nuts, Applegate bacon, Jennie-O turkey. It's a big, steady, boring company that has paid — and raised — its dividend every year for decades. That's the good part: it's safe and pays you about 4.7% a year just to hold it.
The problem is it isn't really growing. Sales have been roughly flat for four years, profits actually dipped, and the stock is down about 19% over the past year while the market went up 20%. It's not wildly expensive, but it's not cheap enough to be a bargain either — Wall Street's average price target ($23.50) is actually below today's price.
Our verdict is Watch: nothing here is broken, but there's no engine pulling the stock higher. Own it if you specifically want a safe dividend; don't expect it to grow your money fast.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe). The company is financially solid, barely moves with the market, and the dividend cushions you — but because earnings aren't growing, there's little room for good surprises.
- Growth Quality 3/10 (weak). Sales are flat and profits are thin for the amount of money tied up in the business.
- Exponential Potential 1/10 (almost none). A giant, mature food company selling more turkey and SPAM is never going to double quickly.
The one big worry: the main reason to own this is the dividend, so anything that pressures earnings — commodity costs, a soft consumer, a bad turkey year — puts pressure on the one thing you're being paid for.
Putting a number on it: our fair-value estimate is $24 against a current price of $21.55 — real upside if our numbers are right.
Our summary metrics
Beta 0.34, modest 2.0× net-debt/EBITDA and a 4.7% dividend — but flat earnings give a rich multiple no cushion.
~2% revenue CAGR, ~6% EPS recovery off a depressed base, ~4% ROIC — a stalled compounder.
A $14B mega-cap staple with flat, commodity-exposed volumes and no acceleration — near-zero multibagger potential.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A $14B mega-cap staple with flat, commodity-exposed volumes and no acceleration — near-zero multibagger potential.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $23.50 (high $25 / low $22; 0 Strong Buy · 6 Buy · 16 Hold · 7 Sell → Hold) — context, not our anchor |
| Valuation | 29× trailing GAAP EPS (distorted by a Q4'25 charge) · ~17× FY26E · ~16× FY27E adj · EV/S 1.3× · EV/EBITDA 15.7× |
| Technicals | Downtrend/basing — $25, −21% off 52-wk high, ~flat vs the 200-DMA, RSI 55, −18.6% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices in the KB; call rests entirely on fundamentals + quant |
| Position sizing | Income/defensive satellite only, ≤1–2% — and only if you specifically want the yield |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for HRL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $21.57, 13% below the 50-day average ($25), 8% below the 200-day average ($23) — a downtrend. 19% below the 52-week high of $27, 9% above the 52-week low of $20.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $21.57 is currently at/below the lower band (potentially oversold) (band $22–$26).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 26.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.31, negative momentum.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = HRL · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Hormel Foods (NYSE: HRL) is a global branded packaged-food company founded in 1891 and headquartered in Austin, Minnesota. It makes and distributes protein-centric shelf-stable and refrigerated foods under more than 30 brands — SPAM, Skippy, Planters, Hormel Black Label bacon, Applegate, Justin's, Herdez, Columbus, Jennie-O turkey, Wholly guacamole. It is a member of the S&P 500 and the S&P 500 Dividend Aristocrats. Fiscal year ends late October.
Revenue mix (FY2025, from filings):
- By segment: Retail $7.46B (62%) · Foodservice $3.94B (33%) · International $709M (6%). Foodservice is the standout — management reports 11 consecutive quarters of organic growth there — while Retail is the largest but slowest.
- By geography: United States $11.44B (~94%) · Non-US $669M (~6%). This is an overwhelmingly US business; international is small but is the faster-growing piece (SPAM exports, China).
The strategic story management keeps pushing is a shift toward value-added, branded protein and away from volatile, commodity-driven businesses — evidenced by the FY26 sale of the whole-bird turkey business (see §9). It is a portfolio-shaping story, not a growth-acceleration story.
2. The expert thesis (no KB coverage)
There is no expert coverage of HRL in the Synthos knowledge base. total_claims = 0; net-bullish voices = 0. No independent analyst or investor in our panel has published a traceable claim on this name.
That is itself a signal: the high-conviction voices Synthos tracks are hunting forward-compounding and exponential names, and a flat, mature packaged-foods staple simply does not attract them. This verdict is therefore entirely fundamentals- and quant-driven — built from the FMP financials, analyst estimates, management's own guidance (half-weighted, §9) and the price/technical record. We fabricate no conviction we do not have: there are no claim_ids to cite because there are none in the file.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Below-average risk | Beta 0.34, net-debt/EBITDA 2.0×, defensive staple demand and a ~4.7% dividend all cushion downside — but flat earnings give the multiple no growth cushion, and the payout ratio is stretched on GAAP EPS. |
| Growth Quality | 3 · Weak | Revenue CAGR ~2%, EPS recovering only ~6% off a depressed FY25 base, ROIC ~4%, ROE ~6%, margins compressing. Durable brands, but a stalled compounder. |
| Exponential Potential | 1 · Very Low | A $14B mega-cap staple with flat, commodity-exposed volumes, negative growth acceleration and no room-to-run. Own it for yield, never for a multibagger. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Foodservice keeps compounding, turkey costs normalize, portfolio-shaping lifts margins; FY27E adj EPS beats to ~$1.70; market re-rates a de-risked Aristocrat to ~18×. | ~$30 (+20%) |
| Base (our anchor) | Guidance roughly holds — FY26E adj EPS ~$1.49, FY27E ~$1.57; a no-growth-but-safe staple earns ~15× forward. | ~$24 (−4%) |
| Bear | Consumer softness + commodity/turkey inflation pressure volumes; adj EPS stalls near ~$1.40 and the multiple de-rates to ~13× as growth doubts persist. | ~$18 (−28%) |
Synthos fair value = the base case, ~$24 (−4%), with the full $18–$30 span as the honest range. This anchor sits essentially on top of the Street's $23.50 consensus — a rare case where our independent model and the sell-side agree the stock is close to fair. Note the Street's average target is below the current price: the market has already bid HRL up toward the top of its analyst range on yield appeal. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HRL is neither — it is a mature, stalled staple:
- Forward growth: revenue CAGR FY25→FY28E ~1.8% ($12.11B → ~$12.76B); adjusted EPS recovering ~6%/yr off a depressed FY25, but that is a rebound, not secular growth.
- Acceleration (the 2nd derivative) is flat-to-negative: revenue has actually shrunk since FY22 ($12.46B → $12.11B FY25); management guides FY26 organic growth of just 1–4%. There is no inflection to ride.
- Room to run: the US packaged-protein TAM is enormous but saturated and slow-growing, and Hormel already holds leading shares in its core categories. At $14B it is not scale-constrained from doubling — it is demand-constrained: the categories themselves barely grow.
- Reinvestment runway: capex is modest (~$310M/yr, ~2.6% of sales) and largely maintenance/technology; the company returns most of its cash as dividends rather than reinvesting for growth — appropriate for a mature name, but the opposite of an exponential.
Exponential Potential: Very Low (1/10). This is a bond-proxy income staple. Own it, if at all, for the ~4.7% yield and low volatility — never for capital-appreciation upside.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $12.11B, roughly flat (FY24 $11.92B; FY23 $12.11B; FY22 $12.46B). Four years of sideways-to-down top line.
- Quarterly trajectory: Q1'26 $3.03B → Q2'26 $2.97B (+2.5% YoY, organic +3%). Steady but low-single-digit.
- Margins: gross 15.7% TTM, operating ~5.8%, net 3.8% TTM. Thin, and gross margin has drifted down from ~17% in FY20. Q2'26 adjusted operating margin was 9.9% (GAAP 7.3%) — the gap is the turkey-divestiture loss.
- Earnings: FY25 GAAP net income $478M, EPS $0.87 — but this is depressed by a Q4'25 charge that produced a −$0.10 quarter (EBITDA collapsed to $67M vs a normal ~$300M+). FY24 was cleaner: net income $805M, EPS $1.47. Do not anchor on the 29× trailing GAAP multiple — it is a one-time-charge artifact. On FY26E adjusted EPS (~$1.49) the forward multiple is ~17×.
- Cash flow: operating CF ~$845M FY25 (down from $1.27B FY24 on working-capital build), capex ~−$311M, FCF ~$534M — enough to cover the ~$633M dividend only thinly this year (dividend-plus-capex coverage ~1.06×). FY24 FCF was ~$1.0B; the FY25 dip bears watching.
- Balance sheet: total debt ~$2.86B, net debt ~$2.19B, net-debt/EBITDA ~2.0×, current ratio 1.9×, interest coverage ~8.9×. Investment-grade and conservative; goodwill+intangibles are ~$6.6B (48% of assets), a legacy of the Planters/Columbus deals.
6. Valuation — priced in or room?
HRL screens cheap on sales (EV/S 1.3×) and fair on EBITDA (EV/EBITDA 15.7×), but the headline 29× trailing GAAP P/E is misleading — it reflects the FY25 one-time charge, not run-rate earnings. On forward adjusted EPS the multiple is ~17× (FY26E $1.49) → ~16× (FY27E $1.57), roughly in line with slow-growth packaged-foods peers. The ~4.7% dividend yield is the real valuation anchor here: it sets a floor (yield-seekers buy the dip) but also a ceiling (there is no earnings growth to re-rate the multiple higher).
A simple triangulation: a no-growth staple with a covered ~4.7% yield and low-single-digit EPS growth is worth roughly 14–16× forward adjusted EPS, i.e. ~$22–$25 — squarely where it trades. Street targets (context): consensus $23.50, high $25, low $22 — and notably the high end sits right at today's price. This is a fairly-valued income holding, not a mispriced opportunity. Not cheap enough to buy for upside; not expensive enough to short.
7. Technicals (computed from EOD price history)
- Trend: weak / basing. $25.00 sits above the 50-DMA ($22.61) and roughly at the 200-DMA ($23.26) after a bounce, but the 12-month picture is a downtrend. MACD mildly positive (+0.79).
- Location: −20.7% off the 52-week high ($31.54), +26.6% off the 52-week low ($19.74). The max drawdown from peak was −54% — a reminder this "safe" staple de-rated hard over the multi-year earnings stall.
- Momentum: RSI(14) 55 — neutral, neither overbought nor oversold.
- Relative strength (the tell): HRL −18.6% 12-mo vs SPY +20.6% and QQQ +30.3% — massive underperformance. It has recovered recently (+13.5% 3-mo, roughly matching SPY's +13.7%), so the bleeding has stopped, but the year has been ugly.
- Read: technicals do not confirm a bull thesis — they show a wounded defensive name basing after a long de-rate. The recent stabilization near the 200-DMA is the most constructive feature; a decisive break above the low-$26s would be the first sign of a trend change.
8. Moat & competitive position
Hormel's moat is brand equity plus scale distribution in shelf-stable and refrigerated protein: SPAM and Skippy are category-defining, Foodservice is a genuine share-gainer (11 straight quarters of organic growth), and the branded portfolio commands shelf space. But the moat is narrow and eroding at the edges: private-label competition in center-store, commodity exposure (turkey, pork) that whipsaws margins, and a consumer trading down. Returns on capital (ROIC ~4%, ROE ~6%) are mediocre — the sign of a moat that protects the business but not high returns.
Peer set (market cap): Coca-Cola Consolidated $15.4B, J.M. Smucker $12.4B, Brown-Forman $12.2B, Clorox $11.8B, BJ's Wholesale $11.4B, Conagra $6.9B, Campbell Soup $7.0B, Lamb Weston $6.3B, Pilgrim's Pride $6.8B. Against packaged-food comps (Smucker, Conagra, Campbell), Hormel's balance sheet is cleaner and its brands stronger, but its growth and returns are middling — it is a quality name in a challenged industry.
9. Management, capital allocation & guidance
- Capital allocation: dividend-first. Hormel is a Dividend Aristocrat (~$633M/yr paid, ~4.7% yield) and prioritizes the payout over buybacks (no meaningful repurchases in FY25) or aggressive M&A. Capex is modest (~2.6% of sales). The GAAP dividend-payout ratio looks alarming (>100% on FY25's charge-depressed EPS) but is ~78% on FY26E adjusted EPS — covered, but not with much room. Watch FCF/dividend coverage.
- Leadership: Jeff Ettinger is serving as interim CEO — a leadership transition is in progress, a modest governance overhang. President John Ghingo runs operations.
- Insider activity: recent Form 4s are routine equity awards to officers (e.g. Chief Supply Chain Officer, EVP Retail, June 2026) and small director in-kind tax withholdings — no cluster of alarming discretionary selling in the sampled window.
- Management's own guidance (half-weighted — their book): the SEC 8-K earnings release (filed 2026-05-28, Q2'26) is a real earnings release and provides explicit forward guidance. For fiscal 2026, management reaffirmed net sales of $12.2–$12.5B and organic growth of 1–4%; reaffirmed adjusted diluted EPS of $1.43–$1.51 (4–10% growth); but cut GAAP EPS guidance to $1.28–$1.37 (from $1.37–$1.46) to reflect the ~$61M loss on the whole-bird turkey divestiture. Management framed Q2 as its "sixth consecutive quarter of organic top-line growth" with each segment growing profit. Treat as self-interested: the adjusted numbers exclude the divestiture loss, and "double-digit adjusted EPS growth" is off an easy comparison. The honest read: guidance confirms low-single-digit organic growth and a portfolio clean-up, not acceleration.
10. Catalysts & what to watch
- Next earnings: 2026-08-27 (Q4'26; Street EPS $0.36, revenue ~$3.05B). Key line: whether Foodservice keeps its organic-growth streak and whether Retail volumes stabilize.
- Turkey/commodity costs: Jennie-O and pork input costs swing margins; the whole-bird divestiture should reduce commodity volatility over time.
- Dividend action: the annual raise (Aristocrat status) — a cut or a skipped raise would be a thesis-breaking negative; a normal raise is the base case.
- CEO transition: appointment of a permanent CEO and any strategy reset.
- FCF/dividend coverage: watch whether FCF recovers toward the ~$1B FY24 level or stays near the ~$534M FY25 trough.
Thesis tripwires (what would change the call): two+ quarters of organic revenue decline; adjusted operating margin slipping below ~9%; FCF failing to cover the dividend; or any signal the dividend raise is at risk. Conversely, a re-acceleration in Foodservice + margin recovery toward 10%+ would move this from Watch toward a tactical income Buy.
11. Key risks
- No growth engine (structural): four years of flat-to-down revenue; the categories themselves barely grow. The stock's total return depends heavily on the dividend.
- Commodity/margin volatility: turkey and pork input costs, plus logistics inflation (management flagged both in Q2'26), compress already-thin (~5.8% operating) margins.
- Consumer trade-down / private label: a value-seeking consumer pressures branded center-store volumes (Retail volume was −2% in Q2'26).
- Dividend dependence: with FCF only thinly covering the payout in FY25, a shock to earnings directly threatens the one reason most holders own it.
- Leadership transition: interim CEO; strategy and capital-allocation continuity are not fully settled.
- No expert conviction: zero KB coverage — there is no independent high-skill voice underwriting an upside case; the call rests solely on quant/fundamentals.
12. Verdict, position sizing & monitoring
Watch. Hormel is a financially sound, low-beta Dividend Aristocrat trading at a fair (not cheap) ~16–17× forward adjusted EPS with a ~4.7% yield — but it is a structurally no-growth staple (revenue flat for four years, ROIC ~4%, EPS only rebounding off a charge-depressed base) with no expert coverage in the Synthos KB and Street sentiment at Hold with an average target below the current price. There is nothing to buy for upside and nothing broken to sell in a panic. It sits in the Watch bucket by design: own it only if you specifically want defensive income.
- Sizing: income/defensive satellite, ≤1–2% — and only for investors who explicitly want the yield and low volatility, not for a growth or total-return sleeve.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Would upgrade toward Buy — Tactical on Foodservice re-acceleration + margin recovery + a clearly-covered, growing dividend; would downgrade toward Avoid on organic revenue declines or dividend-coverage stress. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $25.00.
- Single biggest risk: the dividend is the main reason to own it — anything that pressures earnings pressures the thesis directly.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of HRL in the Synthos knowledge base. This note is fundamentals- and quant-driven; no conviction is claimed beyond the data. Fabricated conviction is structurally impossible (there are no
claim_ids to cite, and none are cited). - Data as-of: fundamentals 2026-04-26 (Q2'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-05-28 SEC 8-K (Q2'26). Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- Management caveat: FY26 guidance is management's own, self-interested framing (adjusted metrics exclude the turkey-divestiture loss); half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").